4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-
RAD51 Inhibitor B02
CAS: 1290541-46-6
Molecular Formula: C22H17N3O
4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]- - Names and Identifiers
4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]- - Physico-chemical Properties
| Molecular Formula | C22H17N3O |
| Molar Mass | 339.39 |
| Melting Point | 174-175o C |
| Solubility | DMSO: ≥ 37 mg/mL |
| Appearance | powder |
| Color | faint yellow to dark yellow |
| Storage Condition | 2-8°C |
| Stability | Hygroscopic |
| In vitro study | RAD51 Inhibitor B02 specifically inhibits human RAD51 (IC 50 =27.4 μM), but not its E. coli homologue RecA (IC 50 >250 μM). The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231. |
| In vivo study | B02 significantly enhances the therapeutic effect of cisplatin on tumor cells in vivo . B02 is tolerated by mice at doses up to 50 mg/kg without obvious body weight loss. No inhibition of tumor growth is observed on mice solely treated by B02. Mice treated with 4 mg/kg cisplatin, however, shows a 33% inhibition of tumor growth. Finally, mice treated with 50 mg/kg B02 and 4 mg/kg cisplatin shows a 66% inhibition of tumor growth. |
4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]- - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 22 - Harmful if swallowed |
| WGK Germany | 3 |
4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]- - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.946 ml | 14.732 ml | 29.465 ml |
| 5 mM | 0.589 ml | 2.946 ml | 5.893 ml |
| 10 mM | 0.295 ml | 1.473 ml | 2.946 ml |
| 5 mM | 0.059 ml | 0.295 ml | 0.589 ml |
Last Update：2024-01-02 23:10:35
4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]- - Reference Information
| biological activity | RAD51 Inhibitor B02 (B02) is an Inhibitor of human RAD51 with an IC50 value of 27.4 μm. |
| Target | IC50: 27.4 μm (hRAD51) |
| in vitro study | RAD51 Inhibitor B02 specifically inhibited human RAD51 (IC 50=27.4 μm), but not its E. coli homolog RecA (IC 50 >250 μm). The combination of B02 with cisplatin has the strongest killing effect on the human breast cancer cells MDA-MB-231. |
| in vivo studies | B02 significant effects the therapeutic effects of cisplatin on tumor cells in vivo . B02 is tolerated by mice at doses up to 50 mg/kg without substantial body weight loss. No inhibition of tumor growth is observed, shows a 33% inhibition of tumor growth. Finally, mice treated with 50 mg/kg B02 and 4 mg/kg cisplatin shows a 66% inhibition of tumor growth. |
Last Update：2024-04-09 21:54:55
![4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[(1E)-2-(3-pyridinyl)ethenyl]-](http://res.chembk.com/assets/images/structure/HY-101462.gif)
Supplier List
Spot supply
Product Name: RAD51 Inhibitor B02 Visit Supplier Webpage Request for quotationCAS: 1290541-46-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: RAD51 Inhibitor B02 Visit Supplier Webpage Request for quotationCAS: 1290541-46-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History